AS1411 aptamer in melanoma therapy: Harnessing targeted strategies for precision treatment
Pathology - Research and Practice · 2025
DOI: 10.1016/j.prp.2025.156124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2025. Verfasst von Monireh Askarzadeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; Department of Immunology, School of Medicine, …. Hauptthemen laut MEDLINE: Melanoma, Aptamers, Nucleotide, Oligodeoxyribonucleotides, Skin Neoplasms. Die Arbeit nennt 134 Literaturangaben. Gefördert von: Mazandaran University of Medical Sciences.
Abstract (Originalsprache)
Melanoma, the fifth most prevalent cancer type in both men and women, is characterized by substantial incidence and mortality rates. Melanoma treatment varies by stage and may include surgery, chemotherapy, immunotherapy, and targeted therapies. The AS1411 aptamer, which targets the overexpressed nucleolin protein in melanoma cells, has emerged as a promising therapeutic agent. It can deliver drugs directly to tumor cells, enhancing treatment efficacy while minimizing side effects. Research highlights the development of nanoparticle-based drug delivery systems, including gold, magnetic, polymeric nanoparticles, and liposomes, all conjugated with AS1411. These systems improve targeting and drug release, demonstrating significant anti-tumor effects in preclinical studies. Additionally, AS1411-conjugated therapies, including peptide and siRNA constructs, show potential in disrupting tumor vasculature and silencing cancer-related genes. Overall, AS1411-modified nanoparticles represent a transformative approach in skin cancer therapy, warranting further clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
- Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: hashemim@mums.ac.ir.
- Pharmaceutical Sciences Research Center, Institute of Herbal Medicines and Metabolic Disorders, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: yazdianr921@gmail.com.
Förderung
- Mazandaran University of Medical Sciences
Zitieren
APA
Askarzadeh, M., Rajabinejad, M., Rafiei, A., Hashemi, M., & Yazdian-Robati, R. (2025). AS1411 aptamer in melanoma therapy: Harnessing targeted strategies for precision treatment. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156124
Vancouver
Askarzadeh M, Rajabinejad M, Rafiei A, Hashemi M, Yazdian-Robati R. AS1411 aptamer in melanoma therapy: Harnessing targeted strategies for precision treatment. Pathology - Research and Practice. 2025. doi:10.1016/j.prp.2025.156124
BibTeX
@article{Askarzadeh2025,
author = {Askarzadeh, Monireh and Rajabinejad, Misagh and Rafiei, Alireza and Hashemi, Maryam and Yazdian-Robati, Rezvan},
title = {AS1411 aptamer in melanoma therapy: Harnessing targeted strategies for precision treatment},
journal = {Pathology - Research and Practice},
year = {2025},
doi = {10.1016/j.prp.2025.156124}
}
EUVIMED